This study investigates genetic testing in patients with stage IB-IIIA non-small cell lung cancer (NSCLC) that has been or will be removed by surgery. Non-small cell lung cancer is a type of lung cancer that grows and spreads more slowly than small cell lung cancer. The purpose of this study is to test the removed cancer tissue for genetic mutations. This helps in enrolling patients in further studies that look at additional treatments after surgery.

Participants will have their tumor tissue and blood samples collected. The study will include detailed follow-up to gather information about their health and treatment outcomes. This information will be used for advanced genetic analysis in collaboration with the National Cancer Institute.

• Who can participate: Adults with stage IB (4 cm or larger), II, or IIIA non-squamous non-small cell lung cancer can participate. They must have a performance status of 0-1 according to the Eastern Cooperative Oncology Group (ECOG) scale.
• Study details: Participants will provide tumor tissue and blood samples for genetic testing. This testing identifies mutations that could guide further treatment. No medication or placebo is involved in this trial. A placebo is an inactive substance that looks like the investigational medicine/vaccine but does not contain any medicine.